SCLC: second-line therapy with lurbinectedin and doxorubicin on trial

被引：0
|
作者：
Simon, Annika
机构：
来源：
PNEUMOLOGIE | 2023年 / 77卷 / 10期
关键词：
D O I：
10.1055/a-2038-6751
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Lurbinectedin ist ein synthetischer Wirkstoff, der die onkogene Transkription des Erbguts hemmt und von der amerikanischen Arzneimittelbehorde FDA eine Zulassung zur Zweitlinientherapie bei kleinzelligem Bronchialkarzinom (SCLC) erhalten hat. Aix et al. wollten nun Sicherheit und Wirksamkeit der Kombination aus Lurbinectedin und Doxorubicin als Zweitlinientherapie bei SCLC prufen und haben eine Phase-III-Studie durchgefuhrt.
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Lurbinectedin (PM01183) with doxorubicin (DOX), an active treatment as second-line therapy in small cell lung cancer (SCLC).
    Forster, Martin
    Calvo, Emiliano
    Olmedo Garcia, Maria Eugenia
    Pilar Lopez Criado, M.
    Moreno, Victor
    Soto-Matos, Arturo
    Holgado, Esther
    Brown, Nicholas F.
    Flynn, Michael
    Boni, Valentina
    Guerra Alia, Eva
    Szyldergemajn, Sergio A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Phase 2 Basket Trial of Lurbinectedin in Second-line SCLC: Characteristics and Outcomes in Treatment Responders
    Subbiah, V.
    Paz-Ares, L.
    Besse, B.
    Moreno, V.
    Peters, S.
    Sala, M. A.
    Lopez-Vilarino, J. A.
    Fernandez, C.
    Kahatt, C.
    Zeaiter, A.
    Zaman, K.
    Delord, J. -P.
    Martinez, M.
    Anton, A.
    Awada, A.
    Kristeleit, R.
    Olmedo, M. E.
    Rubio, M. J.
    Sarantopoulos, J.
    D'Arcangelo, M.
    Santoro, A.
    Trigo, Jose M.
    Sands, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S18 - S19
  • [3] Activity of Lurbinectedin in Second-line SCLC Patients Who Are Candidates for Platinum Rechallenge
    Subbiah, V.
    Paz-Ares, L.
    Besse, B.
    Zaman, K.
    Sala, M. A.
    Lopez-Vilarino, J. A.
    Fernandez, C.
    Kahatt, C.
    Siguero, M.
    Zeaiter, A.
    Arrondeau, J.
    Delord, J. -P.
    Martinez, M.
    Anton, A.
    Trigo, Jose M.
    Wannesson, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S19 - S20
  • [4] COST-EFFECTIVENESS MODELING OF LURBINECTEDIN AS A SECOND-LINE THERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)
    Su, W.
    Rengarajan, B.
    Profant, D.
    Mayo, K.
    Groff, M.
    Tremblay, G.
    Ganti, A. K.
    VALUE IN HEALTH, 2023, 26 (06) : S87 - S87
  • [5] Activity of lurbinectedin in second-line SCLC patients candidates for platinum re-challenge
    Subbiah, V.
    Paz-Ares, L.
    Besse, B.
    Moreno, V.
    Zaman, K.
    Sala Gonzalez, M. A.
    Lopez-Vilarino, J. A.
    Fernandez, C. M.
    Kahatt, C.
    Siguero, M.
    Zeaiter, A.
    Lopez Lopez, R.
    Ponce Aix, S.
    Boni, V.
    Arrondeau, J.
    Delord, J-P.
    Martinez-Aguillo, M.
    De Nicola, L. Wannesson
    Anton Torres, A.
    Trigo Perez, J. M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1034 - S1035
  • [6] Topotecan in second-line therapy of SCLC: Impact on survival?
    Huber, RM
    Gatzemeier, U
    Gosse, H
    von Pawel, J
    Hruska, D
    Mezger, J
    Saal, JG
    Kleinschmidt, R
    Steppert, C
    Steppling, H
    ONKOLOGIE, 2000, 23 : 9 - 12
  • [7] Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial.
    Paz-Ares, Luis G.
    Trigo Perez, Jose Manuel
    Besse, Benjamin
    Moreno, Victor
    Lopez, Rafael
    Angeles Sala, Maria
    Ponce Aix, Santiago
    Marcelo Fernandez, Cristian
    Siguero, Mariano
    Maria Kahatt, Carmen
    Zeaiter, Ali Hassan
    Zaman, Khalil
    Boni, Valentina
    Arrondeau, Jennifer
    Martinez Aguillo, Maite
    Delord, Jean-Pierre
    Awada, Ahmad
    Kristeleit, Rebecca Sophie
    Olmedo Garcia, Maria Eugenia
    Subbiah, Vivek
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Zweitlinientherapie des kleinzelligen Lungenkarzinoms (SCLC)Second-line therapy for small cell lung cancer (SCLC)
    F. Griesinger
    T. Overbeck
    N. Niederle
    Der Onkologe, 2005, 11 (7): : 730 - 740
  • [9] A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting
    Tanaka, Ichidai
    Kawada, Kenji
    Morise, Masahiro
    Hase, Tetsunari
    Hayashi, Hiroaki
    Sokai, Akihiko
    Fukatsu, Asuki
    Kondo, Masashi
    Nomura, Fumio
    Hasegawa, Yoshinori
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (02) : 339 - 345
  • [10] A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting
    Ichidai Tanaka
    Kenji Kawada
    Masahiro Morise
    Tetsunari Hase
    Hiroaki Hayashi
    Akihiko Sokai
    Asuki Fukatsu
    Masashi Kondo
    Fumio Nomura
    Yoshinori Hasegawa
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 339 - 345
12345